Science Backed Success - Perspectives on the Future Growth of Natural Medicines
Malaria Medicines Market Perspectives - Home page | UNICEF · 2018-03-09 · Malaria Medicines...
Transcript of Malaria Medicines Market Perspectives - Home page | UNICEF · 2018-03-09 · Malaria Medicines...
Page 1
UNITAID
Joint UNICEF, UNFPA & WHO Meeting with Manufacturers & Suppliers
Copenhagen, Denmark, 23 Nov. 2015
Malaria Medicines Market
Perspectives
Alexandra Cameron
Ambachew Yohannes
Page 2
Outline
• Gaps in access to antimalarial tools
• Malaria medicines & diagnostics market
overview
• Interventions needed to address challenges
• UNITAID catalytic interventions
Page 4
Malaria Medicines Landscape Anlysis Key Findings (1)
We need
• Improved demand & supply forecast,
• More products for severe malaria.
• Innovative market interventions.
ACTs Market Overview• High market growth (392m in 2013)• Increasing market share for FDCs
& generics• High volumes co-exist with low
access (public sector stock-outs)
Market Shortcoming (in brief) • Low market share of ACTs (private
sector) • High ACT retail prices compared to
older treatments (SP, CQ)• Low availability of prequalified
products for severe malaria
Page 5
Preventive Treatments (SP, SP+AQ) - Market Overview• Few prequalified products• Many generics, low-cost, • Limited incentives for quality-
assured supply• SP resistance threatens future
demand
Market Shortcomings (in Brief)• No alternative to SP for IPTp &
SMC • High quality control failure rates
for SP (28%)• No child-friendly presentations• Low coverage (SMC, IPTp)
Malaria Medicines Landscape Analysis Key Findings (2)
We need
• More quality assured products for SMC & IPTp.
• Child-friendly presentation for SMC, packaging for IPTp
Page 6
Market Overview• Rapid growth in RDT market (45million in
2008 to 319 million in 2013) • Declining prices • Market consolidation around a few
suppliers (90% RDTs from 2 suppliers)
Market Shortcomings (in Brief)• Challenges related to the quality of RDTs • Concentration of suppliers and
associated risk of market disruptions• limited uptake of RDTs • Lack of robust RDT tests for malaria
elimination settings
Malaria Diagnostics Landscape Analysis Key Findings (1)
We need
• Better quality control.
• Improved uptake of RDTs
• New dx for specific settings/groups
Page 7
Next UNITAID Landscape Reports
• Up to date data and information through 2015
• More data & evidence from
– ACT, Artemisinin and RDTs demand forecast
– API market intelligence
• Findings from the ACT Watch market research
– preliminary data shows some major improvements and challenges
Page 8
ACTwatch is a research project implemented by PSI and Ministries of Health in 13 countries
• 45 outlet surveys conducted between 2008-2015
• Most outlet surveys are conducted at national level
• Outlet surveys measure availability, price, and market share in the public and private sectors for malaria medicines and diagnostics
Selected results from ACTwatch
Page 9
• Quality-assured ACTs account for one-third to one-half of all antimalarials distributed in all survey countries, except DRC.
• Non quality-assured ACTs are distributed in some (but not all) countries with striking market share in DRC (~40%) and Zambia (~25%), and a growing problem in Kenya (~20%).
• SP accounts for ¼ to ½ of all private sector antimalarial distribution in each survey country, and 75% in Zambia.
Antimalarials Relative Market Share (1)
Page 10
• Distribution of other non-artemisinin therapies including chloroquineand quinine is declining but these still capture 20-30% of the total market share in Benin, DRC, Madagascar and Nigeria.
• Oral AMT is no longer distributed with the exception of relatively small market share in Nigeria. However, 1 in 4 private providers in Nigeria stock oral AMT.
• Non-oral AMT relative market share remains low with the notable exception of private sector market share in DRC (7%).
Antimalarials Relative Market Share (2)
Page 11
Private sector median price for antimalarial treatment(one adult equivalent treatment dose, 2009 USD)
Page 12
Malaria Diagnostics Market (1)
• Confirmatory testing is largely not available among private sector outlets providing antimalarial medicines.
• Limited availability of malaria testing in the private sector is a key barrier to appropriate case management given large market share of antimalarials in this sector.
• Most testing in the public sector by RDTs, except in DRC & Kenya where microscopy is more common.
• In most countries, more testing in the private sector by microscopy than by RDTs.
Page 13
UNITAID Catalytic Interventions
• ACTs, Artemisninin & RDT demand forecast.
• ACT market intelligence research
• API market intelligence
Market
Intelligence
Quality
Availability
• Artesunate injection & suppositories.
• Dispersible SP+AQ
• RDTs Quality Assurance
Demand
Creation &
uptake
• Private Sector RDTs
• Injectable Artesunate uptake
• Seasonal Malaria Chemoprevention
Page 14
UNITAID landscape & technical reportshttp://www.unitaid.eu/en/resources/publications/technical-reports
sawyerj9
Slide 14
sawyerj9 The most recent ACT forecasting report is Dec 2012, which seems a bit old.
If we have such a slide would be good to summarize the malaria reports/info available from a range of organizations/sources and not just UNITAID.SAWYER, Jacqueline K., 12/11/2015
Page 15
Thank you
UNITAID T: +41 22 791 55 03
F: +41 22 791 48 90
E-mail: [email protected]
http://www.unitaid.org